HK Stock Market Move | IMMUNEONCO-B(01541) rose by more than 10% in early trading. IMM01 has been approved for clinical trials for the treatment of atherosclerosis.

IMMUNEONCO-B(01541) surged by more than 10% in early trading, and as of the time of writing, it has risen by 8.63% to HK$6.67, with a turnover of HK$111.965 million. On the news front, Yimingangke announced that the group has obtained approval from the China National Medical Products Administration (NMPA) to conduct clinical trials of IMM01 (Tidapetsepe) for the treatment of atherosclerosis. It is reported that the group owns the global intellectual property and commercialization rights for IMM01(Tidapetsepe). As of the date of this announcement, the group has a patent family for IMM01(Tidapetsepe), including authorized patents in China, the United States, Japan, and the European Union. Guoyuan International released a research report stating that the company recently regained global rights for IMM2510 and IMM27M, taking back the leading role in overseas clinical research and accelerating global development. The clinical data for 2510 is excellent with good safety, and it has clear differentiation advantages. The company's research and development pipeline continues to grow, increasing its ability to withstand risks. The clinical efficacy data for CD47CD20 dual antibody (IMM0306) is excellent, and it is expected to become a breakthrough drug in the field of autoimmunity. The company is a global innovator in CD47 fusion protein, with a rich pipeline and broad application prospects in oncology, autoimmunity, and cardiovascular fields. With a current market value of only HK$2.7 billion, its value is severely undervalued, and it is recommended to pay close attention.